Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 19;22(1):473.
doi: 10.1186/s12876-022-02577-3.

Threshold of main pancreatic duct for malignancy in intraductal papillary mucinous neoplasm at head-neck and body-tail

Hao Zhou #  1 , Xiaoshuang Li #  2 , Yajie Wang  1 , Zhiyue Wang  2 , Jingrong Zhu  3 , Zhongqiu Wang  1 , Xiao Chen  4
Affiliations

Threshold of main pancreatic duct for malignancy in intraductal papillary mucinous neoplasm at head-neck and body-tail

Hao Zhou et al. BMC Gastroenterol. .

Abstract

Background: Main pancreatic duct (MPD) dilation is a high-risk stigmata/worrisome feature of malignancy in intraductal papillary mucinous neoplasms (IPMNs). The threshold of MPD diameter in predicting malignancy may be related to the lesion location. This study aimed to separately identify the thresholds of MPD for malignancy of IPMNs separately for the head-neck and body-tail.

Materials and methods: A total of 185 patients with pathologically confirmed IPMNs were included. Patient demographic information, clinical data, and pathological features were obtained from the medical records. Those IPMNs with high-grade dysplasia or with associated invasive carcinoma were considered as malignant tumor. Radiological data including lesion location, tumor size, diameter of the MPD, mural nodule, and IPMN types (main duct, MD; branch duct, BD; and mixed type, MT), were collected on computed tomography or magnetic resonance imaging. Serum carbohydrate antigen 19-9 levels, serum carcinoembryonic antigen levels, and the medical history of diabetes mellitus, chronic cholecystitis, and pancreatitis were also collected.

Results: Malignant IPMNs were detected in 31.6% of 117 patients with lesions in the pancreatic head-neck and 20.9% of 67 patients with lesions in the pancreatic body-tail. In MPD-involved IPMNs, malignancy was observed in 54.1% of patients with lesions in the pancreatic head-neck and 30.8% of patients with lesions in the pancreatic body-tail (p < 0.05). The cutoff value of MPD diameter for malignancy was 6.5 mm for lesions in the head-neck and 7.7 mm for lesions in the body-tail in all type of IPMNs. In MPD-involved IPMNs, the threshold was 8.2 mm for lesion in pancreatic head-neck and 7.7 mm for lesions in the body-tail. Multivariate analysis confirmed that MPD diameter ≥ 6.5 mm (pancreatic head-neck) and MPD diameter ≥ 7.7 mm (pancreatic body-tail) were independent predictors of malignancy (p < 0.05). Similar results were observed in MPD-involved IPMNs using 8.2 mm as a threshold.

Conclusion: The thresholds of the dilated MPD may be associated with IPMNs locations. Thresholds of 6.5 mm for lesions in the head-neck and 7.7 mm for lesions in the body-tail were observed. For MPD-involved IPMNs alone, threshold for lesions in the head-neck was close to that in the body-tail.

Keywords: Dysplasia; Intraductal papillary mucinous neoplasms; Invasive carcinoma; Main pancreatic duct; Malignancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Receiver operating curve to calculate the threshold of main pancreatic duct (MPD) in identifying malignancy in all type intraductal papillary mucinous neoplasms (IPMNs). The threshold was 6.5 mm for lesions at head-neck and was 7.7 mm for lesions at body-tail
Fig. 2
Fig. 2
Receiver operating curve to calculate the threshold of main pancreatic duct (MPD) in identifying malignancy in MPD-involved intraductal papillary mucinous neoplasms (IPMNs). The threshold was 8.2 mm for lesions at head-neck and was 7.7 mm for lesions at body-tail
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–753. doi: 10.1016/j.pan.2017.07.007. - DOI - PubMed
    1. Abdeljawad K, Vemulapalli KC, Schmidt CM, Dewitt J, Sherman S, Imperiale TF, et al. Prevalence of malignancy in patients with pure main duct intraductal papillary mucinous neoplasms. Gastrointest Endosc. 2014;79(4):623–629. doi: 10.1016/j.gie.2013.08.024. - DOI - PubMed
    1. Hackert T, Fritz S, Klauss M, Bergmann F, Hinz U, Strobel O, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg. 2015;262(5):875–880. doi: 10.1097/SLA.0000000000001462. - DOI - PubMed
    1. Del Chiaro M, Beckman R, Ateeb Z, Orsini N, Rezaee N, Manos L, et al. Main duct dilatation is the best predictor of high-grade dysplasia or invasion in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2020;272(6):1118–1124. doi: 10.1097/SLA.0000000000003174. - DOI - PubMed
    1. Roch AM, Ceppa EP, Al-Haddad MA, DeWitt JM, House MG, Zyromski NJ, et al. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Ann Surg. 2014;260(4):680–688. doi: 10.1097/SLA.0000000000000927. - DOI - PubMed

MeSH terms